HR00112490476 | OTIDV Award | G2X

MARK CUBAN COST PLUS DRUG COMPANY, PBC

Award IDHR00112490476Agreement typePrototype

Base & Exercised Options

$513.1K

Total value for base award plus exercised options.

Period End Date

Apr 8, 2027

Ultimate completion date for this OTIDV.

Agreement Type

Prototype

Prototype, production, or follow-on production agreement type.

Overview

Award Details

Award ID (PIID): HR00112490476
Award Date: Jan 30, 2026
Fiscal Year: FY2026
Award Value: $513,137
Agreement Type: Prototype
IDV Type: Other Transaction IDV
Extent Competed: Competitive Delivery Order - Fair Opportunity Provided
Consortia: No - Not a Consortia Member
PSC Code: AC12
DoD Acquisition Program: —

Performance & Agency

Awardee: MARK CUBAN COST PLUS DRUG COMPANY, PBC
Awardee UEI: N8P7MQ937WN7
Awarding Agency: DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA)
Awarding Office: DEF ADVANCED RESEARCH PROJECTS AGCY
Funding Agency: DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA)
Funding Office: DEF ADVANCED RESEARCH PROJECTS AGCY
PoP Start Date: Aug 9, 2024
PoP Current End Date: Apr 8, 2027
PoP Ultimate Completion: Apr 8, 2027
Place of Performance: Dallas 75226

OTAs Awarded Under This OTIDV

View the individual OTA awards issued under this OTIDV master agreement.

OTAs Awarded

0

Total Value

$0

Reference ID	Awardee	Agreement Type	Awarding Agency	Award Date	FY	Value

Page 1 of 1